Navigation Links
Safety Analyses of Clinical Data for Bifeprunox in Patients with,Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar,to Placebo

ater than or equal to 5 percent and twice the placebo rate) were gastrointestinal in nature, including nausea, vomiting, constipation and abdominal discomfort.

"These analyses of Phase 2 and Phase 3 studies point out the favorable weight and metabolic profile of patients who received bifeprunox," says Earl Sands, M.D., Vice President, Research and Development at Solvay Pharmaceuticals, Inc. "Patients with schizophrenia have a high risk of developing metabolic side effects, including obesity and high cholesterol."

Philip Ninan, M.D., Vice President, Neuroscience at Wyeth Pharmaceuticals, says, "Through our partnership, Wyeth Pharmaceuticals and Solvay Pharmaceuticals are committed to developing investigational medications for mental health conditions. There is a significant need to expand treatment options and to offer individualized therapy for patients with schizophrenia."

In October 2006, Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. announced that a New Drug Application was submitted to the U.S. Food and Drug Administration for bifeprunox, an investigational antipsychotic for the treatment of schizophrenia and for maintenance of stability. Under the terms of a collaboration agreement entered into in March 2004, Wyeth Pharmaceuticals and Solvay Pharmaceuticals agreed to co-develop and co-commercialize bifeprunox and two other compounds, which are in earlier stages of development, as potential treatments for schizophrenia and other psychiatric conditions. The original compound was discovered by Solvay Pharmaceuticals and is being developed by Wyeth, Solvay Pharmaceuticals and Lundbeck.

Under a new agreement that was announced in January 2007, Wyeth Pharmaceuticals and Solvay Pharmaceuticals will collaborate in a joint discovery effort targeting the identification of small molecules as potential antipsychotic medications. Any compounds discovered as part of the research collaboration will be jointly co-owned and co-patented by Wy
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Managing Preanalytical Processes for Patient Safety
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. New Proof of Genisteins Efficacy and Safety for Osteopenia and Osteoporosis Published in Annals of Internal Medicine
6. First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
7. Phase IIIb Clinical Data Validate the Overall and Cardiovascular Safety Profile of Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) in Patients with Type 2 Diabetes
8. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
9. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
10. Enbrel Safety Data for up to Eight Years in Patients with Juvenile Rheumatoid Arthritis Being Presented at EULAR
11. Repros Reports That Proellex Has Demonstrated Superior Efficacy and Safety in Endometriosis When Compared to Standard of Drug Care
Post Your Comments:
(Date:5/17/2013)... -- Sony Biotechnology Inc. ("Sony") today announced the launch of ... be exhibiting and taking orders for this system at ... San Diego Convention Center in ... - 22.  The SP6800 Spectral Analyzer ... into new and novel functionalities for the immunology, oncology, ...
(Date:5/17/2013)... FARMINGTON, Conn. , May 17, 2013 /PRNewswire-iReach/ ... antibodies and recombinant proteins, is placing renewed emphasis ... on the rise as a number of factors ... opportunity for pharmaceutical makers and their delivery device ... for previously refractory conditions, the growing trend toward ...
(Date:5/17/2013)... , May 17, 2013  Atossa Genetics, Inc. (NASDAQ: ... that Kyle Guse , Chief Financial Officer ... LLP MicroCap Conference on Thursday, May 30, 2013, in ... Hotel. The Company,s presentation is scheduled to ... a live webcast. To access the webcast, go to ...
Breaking Medicine Technology:Sony Biotechnology Inc.'s New Technology for Science Provides Researchers Results in Color 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 2Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference 3
... Roxane Laboratories, Inc. announced today the approval of ... Potassium Tablets USP, 25mg, 50mg and 100mg as ... and 100mg/25mg by the U.S. Food and Drug ... to wholesalers and pharmacies nationwide. Roxane ...
... DiFUSION Technologies Inc., a medical device company ... proprietary CleanFUZE™ anti-microbial technology for orthopedic implants, announced ... line of posterior interbody devices indicated for intervertebral ... to SI, in skeletally mature patients who have ...
Cached Medicine Technology:Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2DiFUSION Technologies Receives 510(k) Clearance of Xiphos™ Interbody Implants for Spinal Fusion 2
(Date:5/18/2013)... FL (PRWEB) May 18, 2013 The ... to the special places we call home. These are the ... maps. They are the locations where the people are friendly ... show takes viewers off the highways and shares the best ... of both nations with an American sports and film celebrity. ...
(Date:5/18/2013)... Family Magazine of Washington DC was awarded the "Best ... Inc. in the category of Summer Camps in DC ... the areas best in the ultimate guide on parenting, kids ... Brenda Hyde, a mother of four and publisher of Family ... vast resources available to them in the DC Metro area. ...
(Date:5/18/2013)... The “Sleep Apnea Diagnostic & Therapeutic Devices ... Servo-Ventilation (ASV), Oral Appliances, Nasal EPAP, Neurostimulation] Global End-user ... studies the major market drivers, restraints, and opportunities in ... , Browse , 147 market ... , 318 pagesand in-depth TOC of ...
(Date:5/18/2013)... Francisco, CA (PRWEB) May 18, 2013 ... appointments for 2013 therapies. At the Ayurvedic Spa ... guidance of panchakarma practitioner and lifestyle recommendations ... Ayurveda, the “knowledge of life", is the traditional healthcare ... that a life of harmony is the basis for ...
(Date:5/18/2013)... Stow, Ohio (PRWEB) May 18, 2013 ... 40th Annual Conference, on May 17-22 in Austin, ... associates gather for educational and networking opportunities. ... cleaning brushes, flexible scope repair capabilities ... presented with valuable educational information on proper instrument ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents "A Place to Call Home" Segment 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Spa Treatments Now Offered at the California College of Ayurveda Panchakarma Center 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2
... Agency advises against everything but jars of peanut butter ... Keebler peanut butter cookies; toll at 453 sickened, 6 ... 17 (HealthDay News) -- The U.S. Food and Drug ... butter products containing peanut butter or peanut butter paste, ...
... peanut butter cookies; FDA asks more companies to test ... sick in 43 states and 1 in Canada, and ... -- Cereal giant Kellogg recalled 16 products containing peanut ... investigation into peanut products possibly contaminated with salmonella. , ...
... chance to win up to $2,500 and promote colon-cancer ... Hutchinson Cancer Research Center,s "Get Screened" video contest - ... the importance of colorectal-cancer screening - has been extended ... Center,s ongoing awareness campaign - "Your colon. Your ...
... Jan. 16 Crdentia Corporation (the "Company") today has ... the Company,s non-reporting status. In conjunction with this, ... conjunction with its transfer agent, Computershare. All share ... listed below for reissuance of new share certificates, although ...
... ARLINGTON, Va., Jan. 16 Despite growing numbers on the ... involved in fatal collisions during 1997-2006 than in years past, ... deaths among drivers 70 and older fell 21 percent during ... of people 70 and older rose 10 percent. Compared with ...
... KJT Group announces a former Harris Interactive executive has joined ... pleased to announce the appointment of J. Scott Moller, M.S. ... Rochester, Mr. Moller has a BA in Economics and Political ... Analysis from the University of Rochester . Before ...
Cached Medicine News:Health News:FDA Warns Consumers Not to Eat Peanut Butter Products 2Health News:FDA Warns Consumers Not to Eat Peanut Butter Products 3Health News:FDA Warns Consumers Not to Eat Peanut Butter Products 4Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 2Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 3Health News:Kellogg Recalls 16 Products as Salmonella Probe Widens 4Health News:'Get Screened' Video Contest Deadline Extended to Jan. 30 2Health News:Crdentia Corp. Finalizes Reverse Stock Split 2Health News:Contrary to Earlier Predictions, Older Driver Fatal Crashes Trend Down 2Health News:Contrary to Earlier Predictions, Older Driver Fatal Crashes Trend Down 3Health News:KJT Group L.L.C. Continues Solid Growth 2
... holds up to eight probe array cartridge ... rotate for controlled hybridization of up to ... temperature control for consistent performance across all ... is available in both 110V and 220V ...
Inquire...
... (WxDxH): 31.1 x 13.6 x 15.3 cm, ... x 20.5 cm, Capacity: 4 - 50 ... 35 mm bottles, 4 - 150 x ... x 80 mm bottle, Power Requirements: 100/120V ...
... Minifold I system consists of four basic components: ... and metal clamping plate (see diagram). The sample ... producing spots, dots, or slots (see below). All ... as an accessory plate in conjunction with a ...
Medicine Products: